Literature DB >> 30615500

Right Ventricular Fibrosis.

Stine Andersen1, Jens Erik Nielsen-Kudsk1, Anton Vonk Noordegraaf2, Frances S de Man2.   

Abstract

The role of right ventricular (RV) fibrosis in pulmonary hypertension (PH) remains a subject of ongoing discussion. Alterations of the collagen network of the extracellular matrix may help prevent ventricular dilatation in the pressure-overloaded RV. At the same time, fibrosis impairs cardiac function, and a growing body of experimental data suggests that fibrosis plays a crucial role in the development of RV failure. In idiopathic pulmonary arterial hypertension and chronic thromboembolic PH, the RV is exposed to a ≈5 times increased afterload, which makes these conditions excellent models for studying the impact of pressure overload on RV structure. With this review, we present clinical evidence of RV fibrosis in idiopathic pulmonary arterial hypertension and chronic thromboembolic PH, explore the correlation between fibrosis and RV function, and discuss the clinical relevance of RV fibrosis in patients with PH. We postulate that RV fibrosis has a dual role in patients with pressure-overloaded RVs of idiopathic pulmonary arterial hypertension and chronic thromboembolic PH: as part of an adaptive response to prevent cardiomyocyte overstretch and to maintain RV shape for optimal function, and as part of a maladaptive response that increases diastolic stiffness, perturbs cardiomyocyte excitation-contraction coupling, and disrupts the coordination of myocardial contraction. Finally, we discuss potential novel therapeutic strategies and describe more sensitive techniques to quantify RV fibrosis, which may be used to clarify the causal relation between RV fibrosis and RV function in future research.

Entities:  

Keywords:  fibrosis; pulmonary hypertension; right ventricle

Mesh:

Year:  2019        PMID: 30615500     DOI: 10.1161/CIRCULATIONAHA.118.035326

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  39 in total

1.  SLIT3 deficiency attenuates pressure overload-induced cardiac fibrosis and remodeling.

Authors:  Lianghui Gong; Shuyun Wang; Li Shen; Catherine Liu; Mena Shenouda; Baolei Li; Xiaoxiao Liu; John A Shaw; Alan L Wineman; Yifeng Yang; Dingding Xiong; Anne Eichmann; Sylvia M Evans; Stephen J Weiss; Ming-Sing Si
Journal:  JCI Insight       Date:  2020-06-18

2.  Delineating the molecular and histological events that govern right ventricular recovery using a novel mouse model of pulmonary artery de-banding.

Authors:  Mario Boehm; Xuefei Tian; Yuqiang Mao; Kenzo Ichimura; Melanie J Dufva; Khadem Ali; Svenja Dannewitz Prosseda; Yiwei Shi; Kazuya Kuramoto; Sushma Reddy; Vitaly O Kheyfets; Ross J Metzger; Edda Spiekerkoetter
Journal:  Cardiovasc Res       Date:  2020-08-01       Impact factor: 10.787

3.  Imaging of cardiac fibroblast activation in patients with chronic thromboembolic pulmonary hypertension.

Authors:  Bi-Xi Chen; Hai-Qun Xing; Juan-Ni Gong; Xiao-Juan Guo; Xiao-Ying Xi; Yuan-Hua Yang; Li Huo; Min-Fu Yang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-15       Impact factor: 9.236

4.  Epigenetic Metabolic Reprogramming of Right Ventricular Fibroblasts in Pulmonary Arterial Hypertension: A Pyruvate Dehydrogenase Kinase-Dependent Shift in Mitochondrial Metabolism Promotes Right Ventricular Fibrosis.

Authors:  Lian Tian; Danchen Wu; Asish Dasgupta; Kuang-Hueih Chen; Jeffrey Mewburn; Francois Potus; Patricia D A Lima; Zhigang Hong; Yuan-Yuan Zhao; Charles C T Hindmarch; Shelby Kutty; Steeve Provencher; Sebastien Bonnet; Gopinath Sutendra; Stephen L Archer
Journal:  Circ Res       Date:  2020-03-27       Impact factor: 17.367

5.  Basement Membrane Extracellular Matrix Proteins in Pulmonary Vascular and Right Ventricular Remodeling in Pulmonary Hypertension.

Authors:  Anjira S Ambade; Paul M Hassoun; Rachel L Damico
Journal:  Am J Respir Cell Mol Biol       Date:  2021-09       Impact factor: 6.914

Review 6.  Cardiac fibrosis.

Authors:  Nikolaos G Frangogiannis
Journal:  Cardiovasc Res       Date:  2021-05-25       Impact factor: 10.787

7.  Xinmai 'an extract enhances the efficacy of sildenafil in the treatment of pulmonary arterial hypertension via inhibiting MAPK signalling pathway.

Authors:  Yaolu Zhu; Yabin Sun; Shichang Zhang; Chuyuan Li; Yiwei Zhao; Boxin Zhao; Guofeng Li
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

8.  α7 Nicotinic acetylcholine receptor mediates right ventricular fibrosis and diastolic dysfunction in pulmonary hypertension.

Authors:  Alexander Vang; Denielli da Silva Gonçalves Bos; Ana Fernandez-Nicolas; Peng Zhang; Alan R Morrison; Thomas J Mancini; Richard T Clements; Iuliia Polina; Michael W Cypress; Bong Sook Jhun; Edward Hawrot; Ulrike Mende; Jin O-Uchi; Gaurav Choudhary
Journal:  JCI Insight       Date:  2021-06-22

9.  Naringin Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension Through Endothelial-To-Mesenchymal Transition Inhibition.

Authors:  Yonghui Wu; Changhong Cai; Yijia Xiang; Huan Zhao; Lingchun Lv; Chunlai Zeng
Journal:  Front Pharmacol       Date:  2021-07-15       Impact factor: 5.810

10.  Acetazolamide Improves Right Ventricular Function and Metabolic Gene Dysregulation in Experimental Pulmonary Arterial Hypertension.

Authors:  Fotios Spyropoulos; Zoe Michael; Benjamin Finander; Sally Vitali; Kosmas Kosmas; Panagiotis Zymaris; Brian T Kalish; Stella Kourembanas; Helen Christou
Journal:  Front Cardiovasc Med       Date:  2021-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.